Zaleplon: A review of its use in the treatment of insomnia

Drugs

Volumn 60, Issue 2, 2000, Pages 413-445

  Dooley, M ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 8 CHLORO 12,12A DIHYDRO 9 OXO 9H,11H AZETIDINO[2,1 C]IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 1 CARBOXYLIC ACID CYCLOPROPYLMETHYL ESTER; ALCOHOL; ALPIDEM; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETEZANIL; CIMETIDINE; DIGOXIN; DIPHENHYDRAMINE; ERYTHROMYCIN; FLUMAZENIL; FLURAZEPAM; HYPNOTIC AGENT; IBUPROFEN; IMIPRAMINE; KETOCONAZOLE; LORAZEPAM; OCINAPLON; PAROXETINE; PYRAZOLOPYRIMIDINE DERIVATIVE; RIFAMPICIN; THIORIDAZINE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CLINICAL TRIAL; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPNOSIS; INSOMNIA; MEMORY; NEUROTOXICITY; NONHUMAN; PSYCHOMOTOR ACTIVITY; REBOUND; RESPIRATORY TRACT DISEASE; REVIEW; SEDATION; SLEEP PATTERN; WITHDRAWAL SYNDROME;

EID: 0033862458     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060020-00014     Document Type: Review

References (75)

1. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia
2. Is there a need for a pure hypnotic? Approaches to the co-diagnosis of insomnia and anxiety
3. Clinical management of patients with insomnia: The role of zopiclone
4. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation survey
5. Management of insomnia
6. Zopiclone: An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia
7. Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: Polysomnographic analysis by means of cyclic alternating pattern
8. Polysomnographic effects of hypnotic drugs: A review
9. Identification of sleep promoting neurons in vitro
10. Redefining a good night's sleep
11. Insomnia: Use of a 'decision tree' to assess and treat
12. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation survey II
13. Overview of insomnia for the primary care physician
14. Zaleplon
15. Zaleplon
16. Zaleplon displays selectivity to recombinant GABA(A) receptors different from zolpidem, zopiclone and benzodiazepines
17. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia
18. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo
19. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
20. Zaleplon and triazolam in humans: Acute behavioral effects and abuse potential
21. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance
22. A placebo-controlled evaluation of single escalating doses of CL 284,846, a non-benzodiazepine hypnotic
23. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor function and memory function in normal male volunteers
24. Zaleplon does not produce residual sedation in a phase-advance model of transient insomnia
25. Evaluation of next-day functioning and residual sedation in healthy subjects: Zaleplon vs. flurazepam
26. Comparison of the effects of zaleplon, zolpidem and triazolam on memory, learning, and psychomotor performance
27. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia
28. A 28-night evaluation of the efficacy, next-day effects and withdrawal potential of zaleplon and zolpidem in outpatients with primary insomnia
29. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia
30. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia
31. The effects of new hypnotic drugs in rats trained to discriminate ethanol
32. Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846
33. Behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazole cue
34. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem
35. The relationship between the pharmacokinetics and pharmacodynamics of zaleplon
36. Safety and efficacy of zaleplon versus zolpidem in outpatients with chronic obstructive pulmonary disease (COPD) and insomnia
37. The comparative pharmacokinetics of zaleplon and zolpidem
38. Zaleplon pharmacokinetics and absolute bioavailability
39. The effects of age and gender on the pharmacokinetics of zaleplon
40. Rapid disappearance of zaleplon from breast milk after oral administration to lactating women
41. The pharmacokinetics and safety of zaleplon in patients with renal impairment
42. The safety and pharmacokinetics of zaleplon in hepatically impaired patients
43. Overview of drug-interaction studies with zaleplon
44. Analysis of potential drug interactions with zaleplon
45. Absence of an interaction between ibuprofen and zaleplon
46. Psychomotor effects of zaleplon and thioridazine coadministration
47. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic
48. Zaleplon: Dose response evaluation in primary insomnia
49. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects
50. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
51. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia
52. Zaleplon decreases sleep latency in outpatients without producing rebound insomnia after 4 weeks of treatment
53. Improvement in sleep latency and sleep quality with zaleplon in elderly patients with primary insomnia
54. Zaleplon is effective in reducing time to sleep onset
55. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia
56. Zaleplon provides safe long-term treatment of insomnia in the elderly
57. The safety of long-term treatment of insomnia with zaleplon
58. The direct economic costs of insomnia in the United States for 1995
59. Use and abuse of the benzodiazepines
60. Hypnosedatives in the elderly: A guide to appropriate use
61. Withdrawal reactions after stopping hypnotics in patients with insomnia